30,936 results match your criteria Prostate Carcinoma


Selectively oxidized cellulose with adjustable molecular weight for controlled release of platinum anticancer drugs.

Biomacromolecules 2019 Feb 22. Epub 2019 Feb 22.

The synthesis of selectively oxidized cellulose, 2,3-dicarboxycellulose (DCC), is optimized for preparation of highly oxidized material for biological applications, which includes control over the molecular weight of the product during its synthesis. Conjugates of DCC and cisplatin simultaneously offer a very high drug-binding efficiency (>90 %) and drug loading capacity (up to 50 wt.%), while retaining good aqueous solubility. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/acs.biomac.8b01807DOI Listing
February 2019

The International Society of Urological Pathology Education web-a web-based system for training and testing of pathologists.

Virchows Arch 2019 Feb 21. Epub 2019 Feb 21.

Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.

Pathology training resources remain scarce in many parts of the world. With rapid economic development comes the need to educate new pathologists to meet the medical care demands. Our aim was to set up a cost-effective system for training and testing the diagnostic skills of pathologists. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00428-019-02540-wDOI Listing
February 2019

Liver metastasis and Heng risk are prognostic factors in patients with non-nephrectomized synchronous metastatic renal cell carcinoma treated with systemic therapy.

PLoS One 2019 20;14(2):e0211105. Epub 2019 Feb 20.

Department of Urology, Center for Prostate Cancer, National Cancer Center, Goyang, Korea.

Objective: This study aimed to determine the prognostic factors of progression-free survival (PFS) and overall survival (OS) in non-nephrectomized patients with synchronous metastatic renal cell carcinoma (mRCC) receiving first-line vascular endothelial growth factor (VEGF)-targeted therapy or immunotherapy.

Methods: Of 70 patients, 57 (81.4%) were treated with targeted therapy, including 5 (7. Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0211105PLOS
February 2019

The repair using a fibular graft of cervical vertebral collapse due to renal cell carcinoma: Late results with a case report.

J Craniovertebr Junction Spine 2018 Oct-Dec;9(4):267-270

Department of Pathology, Research and Training Hospital, Recep Tayyip Erdogan University, Rize, Turkey.

The most common cause of spinal tumors is metastases, but the cervical vertebra is the least common region of spinal metastasis, and relatively, little is published about surgery in metastasis to the cervical vertebra. While spinal metastasis is most often caused by neoplasms originating from the lung, breast, and prostate, renal cell carcinoma (RCC) metastasis is very rare. A 47-year-old patient introduced here presented with severe pain spontaneously on his neck and in his arm. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/jcvjs.JCVJS_32_18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6364372PMC
February 2019

Tumor⁻Microenvironment Interaction: Analysis of Mast Cell Populations in Normal Tissue and Proliferative Disorders of the Canine Prostate.

Vet Sci 2019 Feb 13;6(1). Epub 2019 Feb 13.

Faculty of Veterinary Medicine, University of Teramo, 64100 Teramo, Italy.

Mast cells (MCs) are involved in angiogenesis, tissue remodeling and immunomodulation in several human and animal tumors, although their exact role is still controversial. Since no information is available in canine prostate carcinoma (PC) and normal prostate tissues, the aims of this study were to evaluate the possible correlations between MC distribution, molecular expression and microvessel density (MVD) in normal prostatic tissue and proliferative disorders of the canine prostate. All samples (6 normal, 15 benign prostate hyperplasia-BPH, 8 PC) were stained with Toluidine Blue and immunohistochemically evaluated for tryptase, c-Kit (CD117) and CD31. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/vetsci6010016DOI Listing
February 2019

Neuroendocrine prostate carcinoma cells originate from the p63-expressing basal cells but not the pre-existing adenocarcinoma cells in mice.

Cell Res 2019 Feb 18. Epub 2019 Feb 18.

Department of Molecular and Cellular Biology, and Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, One Baylor Plaza, Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41422-019-0149-4DOI Listing
February 2019

Detection of androgen receptor (AR) and AR-V7 in small cell prostate carcinoma: Diagnostic and therapeutic implications.

Asian J Urol 2019 Jan 28;6(1):109-113. Epub 2018 Sep 28.

Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Objective: Small cell prostate carcinoma (SCPC) is a rare and highly malignant subtype of prostate cancer. SCPC frequently lacks androgen receptor (AR) and prostate-specific antigen (PSA) expression, and often responds poorly to androgen deprivation therapy (ADT). AR splice variant-7 (AR-V7) is a truncated AR protein implicated in resistance to AR-targeting therapies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ajur.2018.09.003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6363596PMC
January 2019

Squamous Carcinoma of the Neovagina after Male-to-Female Reconstruction Surgery: A Case Report and Review of the Literature.

Case Rep Obstet Gynecol 2019 16;2019:4820396. Epub 2019 Jan 16.

Department of Gynaecology, University Hospital Zurich, Zurich, Switzerland.

Squamous cell carcinoma (SCC) of the neovagina after genital reconstruction surgery is a rare occurrence with only very few cases published up to the present. We report a case of a 43-year-old transgender woman who developed neovaginal SCC 23 years after vaginoplasty. The patient tested positive for high-risk human papillomavirus (HPV). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2019/4820396DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354136PMC
January 2019

Molecular Status of BRAF Mutation in Prostate Adenocarcinoma: The Analysis of 100 Cases in North-East of IRAN.

Iran J Pathol 2018 25;13(4):415-421. Epub 2018 Sep 25.

Cancer Molecular Pathology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.

Background And Objective: mutations were studied in various populations for prostate carcinoma (PC); however, mutations in BRAF gene are unusual compared to . Oncogenic activating of BRAF mutations were studied lately in almost 0%10% of prostate cancer cases.

Methods: In this retrospective study, we gathered 100 formalin-fixed paraffin-embedded samples of prostate adenocarcinoma. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358555PMC
September 2018

DIAGNOSIS AND MANAGEMENT OF PAGET'S DISEASE OF BONE - SERIES OF 8 CASES.

Acta Ortop Bras 2019 Jan-Feb;27(1):31-32

Universidade Estadual de São Paulo Júlio de Mesquita Filho (UNESP), Faculdade de Medicina de Botucatu, Botucatu, SP, Brazil.

Paget's disease of bone is a chronic condition characterized by focal abnormalities of absorption and formation of bone, and it may lead to anatomical deformities, pain, fractures, and malignant transformation. It is common in the UK, Australia, New Zealand, and North America and has a strong hereditary component, affecting first- to third-degree relatives. The etiology remains unclear and treatment is based on control of the disease with bisphosphonates, with the aim of relieving symptoms and correcting laboratory abnormalities. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1590/1413-785220192701161107DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6362702PMC
February 2019

Prostatic ductal adenocarcinoma with cribriform architecture has worse prognostic features than non-cribriform-type.

Ann Diagn Pathol 2019 Feb 10;39:59-62. Epub 2019 Feb 10.

Department of Pathology and Laboratory Medicine, BC Cancer Agency, Vancouver, BC, Canada. Electronic address:

Prostatic ductal adenocarcinoma (PDA) is a rare histologic subtype of prostate cancer characterized by large glands lined with tall columnar pseudostratified epithelium. PDA has several architectural patterns, with papillary and cribriform being the most common. The cribriform pattern of acinar carcinoma has shown to be associated with a worse prognosis in terms of disease progression and disease-specific mortality. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.anndiagpath.2019.02.007DOI Listing
February 2019

Contemporary trends of pelvic lymph node dissection at radical cystectomy for urothelial carcinoma of urinary bladder and associated cancer specific mortality and complications: comparison between octogenarian versus younger patients.

Cancer Epidemiol 2019 Feb 13;59:135-142. Epub 2019 Feb 13.

Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Québec, Canada; Division of Urology, University of Montreal Hospital Center (CHUM), Montreal, Quebec, Canada.

Background: We analysed contemporary pelvic lymph node dissection (PLND) trend during radical cystectomy (RC) for urothelial carcinoma of urinary bladder (UCUB), as well as PLND association with cancer specific mortality (CSM) and complications after stratification according to octogenarian vs. younger age.

Materials And Methods: Within the SEER and NIS databases, respectively 10,427 (T2 and T3 stages) and 19,203 (all T-stages) RC patients (2004-2015) for UCUB were identified. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.canep.2019.02.002DOI Listing
February 2019
1 Read

Anticancer and antimetastatic potential of enterolactone: clinical, preclinical and mechanistic perspectives.

Eur J Pharmacol 2019 Feb 13. Epub 2019 Feb 13.

Pharmaceutical Sciences, Poona College of Pharmacy, Bharati Vidyapeeth (Deemed to be University), Pune, Maharashtra 411038, India.

Currently cancer is the second leading cause of death globally and worldwide incidence and mortality rates of all cancers of males and females are rising tremendously. In spite of advances in chemotherapy and radiation, metastasis and recurrence are considered as the major causes of cancer related deaths. Hence there is a mounting need to develop new therapeutic modalities to treat metastasis and recurrence in cancers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejphar.2019.02.022DOI Listing
February 2019
1 Read

Comparison of perioperative outcomes between open and minimally invasive nephroureterectomy: A population-based analysis.

Int J Urol 2019 Feb 12. Epub 2019 Feb 12.

Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Quebec, Canada.

Objectives: To examine intraoperative and postoperative morbidity and mortality, as well as the impact on length of stay and total hospital charges of minimally invasive nephroureterectomy compared with open nephroureterectomy in patients with upper tract urothelial carcinoma.

Methods: Within the National Inpatient Sample (2008-2013), we identified patients with non-metastatic upper tract urothelial carcinoma treated with either minimally invasive nephroureterectomy or open nephroureterectomy. We relied on inverse probability of treatment weighting to reduce the effect of inherent differences between open nephroureterectomy versus minimally invasive nephroureterectomy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/iju.13916DOI Listing
February 2019
1 Read

Epithelial-To-Mesenchymal Transition Markers and CD44 Isoforms Are Differently Expressed in 2D and 3D Cell Cultures of Prostate Cancer Cells.

Cells 2019 Feb 11;8(2). Epub 2019 Feb 11.

Department of Biomedical Sciences for Health, Università degli Studi di Milano, via Mangiagalli 31, 20133 Milan, Italy.

Three-dimensional (3D) cell cultures allow the mimic of functions of living tissues andprovide key information encoded in tissue architecture. Considered the pivotal role of epithelial-tomesenchymaltransition (EMT) in carcinoma progression, including prostate cancer (PCa), weaimed at investigating the effect of the 3D arrangement on the expression of some key markers ofEMT in cultured human prostate cancer (PCa) cells, to better understand PCa cell behavior. PC3 andDU145 PCa cells were cultured in RPMI cell culture medium either in 2D-monolayers or in 3Dspheroids. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cells8020143DOI Listing
February 2019

PET imaging in renal cancer.

Curr Opin Oncol 2019 Feb 11. Epub 2019 Feb 11.

Department of Nuclear Medicine & PET Centre, Aarhus University Hospital, Denmark.

Purpose Of Review: Worldwide, over 400 000 new cases of kidney cancer were diagnosed and over 175 000 deaths anticipated in 2018. It is ranked as the 14th most common cancer in women and 9th most common in men. Imaging is important for initial detection, staging, and monitoring to assist treatment planning, but conventional anatomic imaging is limited. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CCO.0000000000000518DOI Listing
February 2019
3 Reads

SENP1 Interacts with HIF1α to Regulate Glycolysis of Prostatic Carcinoma Cells.

Int J Biol Sci 2019 1;15(2):395-403. Epub 2019 Jan 1.

Department of Urology, the First Affiliated Hospital of Harbin Medical University, Harbin, China.

Hypoxic microenvironment inside the tumor forces tumor cells to up-regulate the glycolytic pathway to maintain a sufficient energy supply for tumor growth. Activation of HIF1α under hypoxia condition is able to regulate the expression of glycolysis-related genes, and results in the proliferation and metastasis of cancer cells. However, the mechanism underlying HIF1α activation and glycolysis induction by hypoxia remains unclear. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7150/ijbs.27256DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6367554PMC
January 2019

Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial.

Lancet Oncol 2019 Feb 7. Epub 2019 Feb 7.

Department of Oncology, Phase 1 Unit, Rigshospitalet, Copenhagen, Denmark.

Background: Tisotumab vedotin is a first-in-human antibody-drug conjugate directed against tissue factor, which is expressed across multiple solid tumour types and is associated with poor clinical outcomes. We aimed to establish the safety, tolerability, pharmacokinetic profile, and antitumour activity of tisotumab vedotin in a mixed population of patients with locally advanced or metastatic (or both) solid tumours known to express tissue factor.

Methods: InnovaTV 201 is a phase 1-2, open-label, dose-escalation and dose-expansion study done at 21 centres in the USA and Europe. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(18)30859-3DOI Listing
February 2019
2 Reads

Long-Term Implications of a Positive Post Treatment Biopsy Among Patients Treated with External Beam Radiotherapy for Clinically Localized Prostate Cancer.

J Urol 2019 Feb 5. Epub 2019 Feb 5.

From the Department of Radiation Oncology, Department of Pathology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 1275 York Ave, N,Y., N.Y. 10065.

Purpose: To determine the prognostic importance of a positive post-treatment biopsy after prostate radiotherapy.

Materials And Methods: 382 patients underwent a post-treatment biopsy after external beam radiotherapy (EBRT) for clinically localized prostate cancer. Post-treatment biopsies were classified as positive (prostatic adenocarcinoma without typical radiation-induced changes), negative (no evidence of carcinoma) or adenocarcinoma with severe treatment effect (STE). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JU.0000000000000110DOI Listing
February 2019
1 Read

microRNA-205 and microRNA-338-3p Reduces Cell Apoptosis in Prostate Carcinoma Tissue and LNCaP Prostate Carcinoma Cells by Directly Targeting the B-Cell Lymphoma 2 (Bcl-2) Gene.

Med Sci Monit 2019 Feb 11;25:1122-1132. Epub 2019 Feb 11.

Department of Oncology, The Third Xiangya Hospital of Central South University, Changsha, Hunan, China (mainland).

BACKGROUND The inhibitor of apoptosis, B-cell lymphoma 2 (Bcl-2), is encoded by the BCL2 gene. Previous studies have shown that microRNAs are downregulated in prostate cancer. This study aimed to investigate the role of microRNA-205 and microRNA-338-3p and cell apoptosis in prostate carcinoma tissue and the LNCaP human prostate adenocarcinoma cell line by directly targeting the BCL2 gene and Bcl-2 protein expression. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12659/MSM.912148DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6380162PMC
February 2019
2 Reads

What Survival Benefits are Needed to Make Adjuvant Sorafenib Worthwhile After Resection of Intermediate- or High-Risk Renal Cell Carcinoma? Clinical Investigators' Preferences in the SORCE Trial.

Kidney Cancer 2018 Aug 1;2(2):123-131. Epub 2018 Aug 1.

NHMRC Clinical Trials Centre, University of Sydney, Camperdown, NSW, Australia.

Background: Decisions about adjuvant therapy involve trade-offs between possible benefits and harms.

Objective: We sought to determine the survival benefits that clinical investigators would judge as sufficient to warrant treatment with adjuvant sorafenib in the SORCE trial after nephrectomy for apparently localised renal cell carcinoma (RCC).

Methods: A subset of clinical investigators in the SORCE trial completed a validated questionnaire that elicited the minimum survival benefits they judged sufficient to warrant one year of adjuvant sorafenib in scenarios with hypothetical baseline survival times of 5 years and 15 years, and baseline survival rates at 5 years of 65% and 85%. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/KCA-180038DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6364092PMC
August 2018
1 Read

Benefit of nephron sparing surgery translates into lower cancer specific mortality in patients with localized renal cell carcinoma.

Ann Transl Med 2018 Dec;6(Suppl 2):S104

Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Québec, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/atm.2018.11.37DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6330610PMC
December 2018
1 Read

SAMD5 mRNA was overexpressed in prostate cancer and can predict biochemical recurrence after radical prostatectomy.

Int Urol Nephrol 2019 Feb 9. Epub 2019 Feb 9.

Department of Urology, National Key Clinical Specialty of Urology, The Second Hospital of Tianjin Medical University, Tianjin, 300211, China.

Purpose: To identify a novel biomarker that can predict biochemical recurrence (BCR) after radical prostatectomy.

Methods: The gene expression profile of SAMD5 in prostate cancer was explored based on the oncomine database and The Cancer Genomic Atlas (TCGA). The follow-up information and clinical pathologic variables were extracted from the following cohort study: TCGA_prostate carcinoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11255-019-02096-3DOI Listing
February 2019

Therapeutic options for first-line metastatic castration-resistant prostate cancer: Suggestions for clinical practise in the CHAARTED and LATITUDE era.

Cancer Treat Rev 2019 Jan 7;74:35-42. Epub 2019 Jan 7.

Departmental Unit of Clinical and Experimental Uro-Andrologic Oncology, Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale, Napoli, Italy. Electronic address:

In few years the scenario of metastatic prostate carcinoma treatment has radically changed due to improved knowledge of those mechanisms responsible of prostatic cancer cells survival and proliferation. Five new therapeutic agents (abiraterone acetate, enzalutamide, cabazitaxel, radium-223, sipuleucel-T), all able to improve overall survival, have been introduced in the management of metastatic castration-resistant prostate cancer. Moreover, recent evidences showed that adding docetaxel chemotherapy or abiraterone acetate to androgen deprivation therapy significantly increases overall survival of de novo castration-sensitive metastatic prostate cancer patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2019.01.002DOI Listing
January 2019

Estimation of Solid Tumor Doubling Times from Progression-Free Survival Plots Using a Novel Statistical Approach.

AAPS J 2019 Feb 8;21(2):27. Epub 2019 Feb 8.

Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, The State University of New York at Buffalo, 455 Kapoor Hall, Buffalo, New York, 14214, USA.

Tumor doubling time can significantly affect the outcome of anticancer therapy, but it is very challenging to determine. Here, we present a statistical approach that extracts doubling times from progression-free survival (PFS) plots, which inherently contains information regarding the growth of solid tumors. Twelve cancers were investigated and multiple PFS plots were evaluated for each type. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1208/s12248-019-0302-5DOI Listing
February 2019
1 Read

Perioperative blood transfusion affects oncologic outcomes after nephrectomy for renal cell carcinoma: A systematic review and meta-analysis.

Urol Oncol 2019 Feb 5. Epub 2019 Feb 5.

Department of Urology, Medical University of Vienna, Vienna, Austria; Department of Urology, Weill Cornell Medical College, New York, NY; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX; Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria. Electronic address:

Aim: To investigate the association of perioperative blood transfusion (PBT) with oncologic outcomes in patients with renal cell carcinoma (RCC), we conducted a systematic review and meta-analysis of the literature to clarify the long-term oncologic effect of PBT in patients undergoing nephrectomy for RCC.

Materials And Methods: We searched the MEDLINE, Web of Science, Cochrane Library and Scopus on 15th April 2018 to identify studies that compared patients who received PBT undergoing radical or partial nephrectomy for RCC to patients who did not with the aim of evaluating its impact on overall mortality (OM), cancer-specific mortality (CSM) and disease recurrence using multivariable cox regression analysis.

Results: A total of 19,681 patients in 7 studies matched the selection criteria for the systematic review and meta-analysis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urolonc.2019.01.018DOI Listing
February 2019
1 Read

Widespread and Functional RNA Circularization in Localized Prostate Cancer.

Cell 2019 Feb;176(4):831-843.e22

Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada; Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada. Electronic address:

The cancer transcriptome is remarkably complex, including low-abundance transcripts, many not polyadenylated. To fully characterize the transcriptome of localized prostate cancer, we performed ultra-deep total RNA-seq on 144 tumors with rich clinical annotation. This revealed a linear transcriptomic subtype associated with the aggressive intraductal carcinoma sub-histology and a fusion profile that differentiates localized from metastatic disease. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00928674193005
Publisher Site
http://dx.doi.org/10.1016/j.cell.2019.01.025DOI Listing
February 2019
6 Reads

[Update Urooncology: News from major scientific meetings 2018].

Aktuelle Urol 2019 Feb 7;50(1):23-31. Epub 2019 Feb 7.

We are living in exciting times for urological oncology. The numbers of clinical trials are ever rising, a stream of new substances for tumour therapy is introduced. As it is more challenging than ever to obtain an overview as a clinician, this article aims to summarise the most important news with regard to the 3 most eminent urological tumour entities. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1055/a-0759-3664DOI Listing
February 2019
1 Read

Elucidation of the chemopreventive role of stigmasterol against Jab1 in Gall bladder carcinoma.

Endocr Metab Immune Disord Drug Targets 2019 Feb 6. Epub 2019 Feb 6.

Department of Surgical Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow. India.

Background: Plant sterols have proven a potent anti-proliferative and apoptosis inducing agent against several carcinomas including breast and prostate cancers. Jab1 has been reported to be involved in the progression of numerous carcinomas. However, antiproliferative effects of sterols against Jab1 in gall bladder cancer have not been explored yet. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1871530319666190206124120DOI Listing
February 2019
2 Reads

Tumor-Specific S/G-Phase Cell Cycle Arrest of Cancer Cells by Methionine Restriction.

Methods Mol Biol 2019 ;1866:49-60

AntiCancer, Inc., San Diego, CA, USA.

Cancer cells require elevated amounts of methionine (MET) and arrest their growth under conditions of MET restriction (MR). This phenomenon is termed MET dependence. Fluorescence-activated cell sorting (FACS) first indicated that the MET-dependent SV40-transformed cancer cells were arrested in the S and G phases of the cell cycle when under MR. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/978-1-4939-8796-2_5
Publisher Site
http://dx.doi.org/10.1007/978-1-4939-8796-2_5DOI Listing
January 2019
8 Reads

Prostate cancer with comedonecrosis is frequently, but not exclusively, intraductal carcinoma: a need for reappraisal of grading criteria.

Histopathology 2019 Feb 5. Epub 2019 Feb 5.

Department of Urology, Vattikuti Urology Institute, Henry Ford Health System, Detroit, MI, USA.

Aims: Comedonecrosis in prostate cancer has always been Gleason pattern 5. However, we aimed to evaluate how intraductal carcinoma (not graded) with comedonecrosis should be considered.

Methods And Results: From 52 radical prostatectomy patients, 40 were informative and evaluated with immunohistochemistry for basal cells. Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1111/his.13833
Publisher Site
http://dx.doi.org/10.1111/his.13833DOI Listing
February 2019
2 Reads

Iatrogenic Disease of the Genitourinary Tract.

Authors:
Helen P Cathro

Adv Anat Pathol 2019 Feb 1. Epub 2019 Feb 1.

Department of Pathology and Laboratory Medicine, University of Virginia, Charlottesville, VA.

Iatrogenic disease is defined as illness caused by diagnostic procedures or treatment given by health care professionals. More recently described treatment complications involving the genitourinary tract include newly recognized variants of renal carcinoma in the setting of dialysis/end-stage renal disease, treatment effect in genitourinary carcinomas, and medical renal disease caused by drug therapies, including immunotherapy. The objective of this review is to cover iatrogenic inflammatory diseases, pseudotumors and tumors of the kidney, bladder, prostate, testis and paratestis of most interest to surgical pathologists. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PAP.0000000000000226DOI Listing
February 2019

MiR-1299 functions as a tumor suppressor to inhibit the proliferation and metastasis of prostate cancer by targeting NEK2.

Eur Rev Med Pharmacol Sci 2019 Jan;23(2):530-538

Department of Urology, Beijing Friendship Hospital, Capital Medical University, Beijing, China.

Objective: The aim of this study was to investigate the inhibitory role of microRNA-1299 (miR-1299) in prostate cancer, and to explore the possible underlying mechanism.

Patients And Methods: The expression of miR-1299 in 35 PCa tissues and para-carcinoma tissues, as well as PCa cell lines (PC-3) and prostatic epithelial cell line (RWPE-1), was detected by quantitative Real Time-Polymerase Chain Reaction (qRT-PCR). Then, we explored the possible targets of miR-1299 by searching online databases. Read More

View Article

Download full-text PDF

Source
http://www.europeanreview.org/article/16865
Publisher Site
http://dx.doi.org/10.26355/eurrev_201901_16865DOI Listing
January 2019
2 Reads

The Prognostic Value of Pretreatment Plasma Fibrinogen in Urological Cancers: A Systematic Review and Meta-analysis.

J Cancer 2019 1;10(2):479-487. Epub 2019 Jan 1.

Department of Urology, Peking University First Hospital, Beijing 100034, China.

Growing evidence suggests pretreatment fibrinogen can serve as a prognostic marker in various malignancies. However, there are contradictory results about the prognostic role of fibrinogen in urological cancers. We conducted a meta-analysis to evaluate the association between pretreatment plasma fibrinogen and survival outcomes in urological cancers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7150/jca.26989DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360290PMC
January 2019
1 Read

Drug candidate identification based on gene expression of treated cells using tensor decomposition-based unsupervised feature extraction for large-scale data.

Authors:
Y-H Taguchi

BMC Bioinformatics 2019 Feb 4;19(Suppl 13):388. Epub 2019 Feb 4.

Department of Physics, Chuo University, 1-13-27 Kasuga, Bunkyo-ku, Tokyo, 112-8551, Japan.

Background: Although in silico drug discovery is necessary for drug development, two major strategies, a structure-based and ligand-based approach, have not been completely successful. Currently, the third approach, inference of drug candidates from gene expression profiles obtained from the cells treated with the compounds under study requires the use of a training dataset. Here, the purpose was to develop a new approach that does not require any pre-existing knowledge about the drug-protein interactions, but these interactions can be inferred by means of an integrated approach using gene expression profiles obtained from the cells treated with the analysed compounds and the existing data describing gene-gene interactions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12859-018-2395-8DOI Listing
February 2019

Sclerin, a New Cytotoxic Cyclononapeptide from .

Molecules 2019 Feb 3;24(3). Epub 2019 Feb 3.

Institute of Bio-Organic Chemistry Antonio González, Department of Organic Chemistry, University of La Laguna, Astrofísico Francisco Sánchez 2, 38206 La Laguna, Tenerife, Spain.

A new cytotoxic cyclononapeptide, sclerin, cyclo(⁻Dab⁻Ser⁻Tyr⁻Gly⁻Thr⁻Val⁻Ala⁻ Ile⁻Pro⁻) (), was isolated from the methanol extract of the seeds of , together with the known metabolite, cyclosenegalin A, cyclo(⁻Pro⁻Gly⁻Leu⁻Ser⁻Ala⁻Val⁻Thr⁻) (). The planar structures for the two compounds were established by comprehensive analysis of NMR and ESI-HRMS data, and the absolute stereochemistry was stablished by Marfey's method. Compound showed moderate cytotoxic activity against the human prostate carcinoma cell line DU-145 at µM concentration. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/molecules24030554DOI Listing
February 2019
1 Read

Synthesis of substituted biphenyl methylene indolinones as apoptosis inducers and tubulin polymerization inhibitors.

Bioorg Chem 2019 Jan 29;86:210-223. Epub 2019 Jan 29.

Department of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad 500 037, India; School of Pharmaceutical Education and Research (SPER), Jamia Hamdard, New Delhi 110062, India. Electronic address:

A new series of biphenyl methylene indolinones has been designed, synthesized and evaluated for their in vitro antiproliferative activity against various cancer cell lines like DU-145 (prostate cancer cell line), 4T1 (mouse breast cancer cell line), MDA-MB-231 (human breast cancer cell line), BT-549 (human breast cancer cell line), T24 (human urinary bladder carcinoma cell line), and HeLa (cervical cancer cell line). Among the series, compound 10e showed potent in vitro cytotoxic activity against HeLa and DU-145 cancer cell lines with IC value of 1.74 ± 0. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00452068183105
Publisher Site
http://dx.doi.org/10.1016/j.bioorg.2019.01.063DOI Listing
January 2019
1 Read
2.152 Impact Factor

Pentafluorophenyl substitution of natural di(indol-3-yl)methane strongly enhances growth inhibition and apoptosis induction in various cancer cell lines.

Chem Biodivers 2019 Feb 4. Epub 2019 Feb 4.

Universitat Bayreuth, Organische Chemie 1, Universit�tsstrasse 30, 95440, Bayreuth, GERMANY.

Di(indol-3-yl)methane (DIM, 1) is a known weakly antitumoral compound formed by digestion of indole-3-carbinol, an ingredient of various Brassica vegetables. Out of a series of nine fluoroaryl derivatives of 1, three pentafluorophenyl derivatives 2c, 2h and 2i were identified that exhibited a two to five times greater anti-proliferative effect and an increased apoptosis induction when compared with 1 in the following carcinoma cell lines: BxPC-3 pancreas, LNCaP prostate, C4-2B prostate, PC3 prostate and the triple-negative MDA-MB-231 breast carcinoma. Compound 2h was particularly efficacious against androgen-refractory C4-2B prostate cancer cells (IC50 = 6. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cbdv.201900028DOI Listing
February 2019

Six-transmembrane epithelial antigen of the prostate 1 is associated with tumor invasion and migration in endometrial carcinomas.

J Cell Biochem 2019 Feb 3. Epub 2019 Feb 3.

Department of Maternal and Child Health, School of Public Health, Shandong University, Jinan, China.

Six-transmembrane epithelial antigen of the prostate 1 (STEAP1), a member of the STEAP family, is a general tumor antigen. However, no information has been available to date regarding the function of STEAP1 in the progression of endometrial carcinoma. In this study, we used in vitro and in vivo strategies to prove that STEAP1 plays an important role in the progression of endometrial carcinoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcb.28393DOI Listing
February 2019
1 Read

Further application of hyperbaric oxygen in prostate cancer.

Med Gas Res 2018 Oct-Dec;8(4):167-171. Epub 2019 Jan 9.

Department Department of Urology and Neurosurgery, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, China.

Hyperbaric oxygen therapy (HBOT) has been used as an adjuvant treatment for multiple pathological states, which involves hypoxic conditions. Over the past 50 years, HBOT has been recommended and used in a wide variety of medical conditions, clinically in the treatment of ischemic or nonhealing wounds and radiation-injured tissue, and in the treatment of malignancy. The mechanism of this treatment is providing oxygen under pressure which is higher than the atmosphere thus increasing tissue oxygen concentration. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/2045-9912.248268DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6352573PMC
January 2019
1 Read

Clinical characteristics, treatment outcomes and potential novel therapeutic options for patients with neuroendocrine carcinoma of the prostate.

Oncotarget 2019 Jan 1;10(1):17-29. Epub 2019 Jan 1.

Department of Medical Oncology, National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany.

Background: Neuroendocrine carcinomas of the prostate (NEPCs) are rare tumors with poor prognosis. While platinum and etoposide-based chemotherapy regimens (PE) are commonly applied in first-line for advanced disease, evidence for second-line therapy and beyond is very limited.

Methods: Retrospective analysis of all patients with NEPCs including mixed differentiation with adenocarcinoma component and well differentiated neuroendocrine tumors (NETs, carcinoids) at two high-volume oncological centers between 12/2000 and 11/2017. Read More

View Article

Download full-text PDF

Source
http://www.oncotarget.com/fulltext/26523
Publisher Site
http://dx.doi.org/10.18632/oncotarget.26523DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6343754PMC
January 2019
1 Read

A Rare Case of Liver Metastasis from Prostate Cancer Mimicking Hepatocellular Carcinoma on Immunohistochemistry: Role of F-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Diagnosis.

Indian J Nucl Med 2019 Jan-Mar;34(1):54-56

Department of Pathology, VPS Lakeshore Hospital, Kochi, Kerala, India.

We present a case with space-occupying lesion in cirrhotic liver, diagnosed as hepatocellular carcinoma on immunohistochemistry, who underwent F-18 fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) and showed FDG-avid lesions in liver as well as in the prostate. These findings guided in establishing the diagnosis of prostate cancer, metastasizing to liver by performing additional immunohistochemical markers. PET/CT was also useful in identifying coexisting non-Hodgkin's lymphoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/ijnm.IJNM_110_18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6352627PMC
February 2019

Immunotherapy for genitourinary tumors.

Int J Urol 2019 Feb 1. Epub 2019 Feb 1.

Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan.

The present review provides an update about the major achievements and recent advances of immunotherapy in renal cell carcinoma, urothelial carcinoma, and prostate cancer. Although the treatment strategy for renal cell carcinoma and urothelial carcinoma includes traditional cancer immunotherapies, such as interleukin-2 and interferon-alfa, the clinical outcomes of these therapies are unsatisfactory. In recent years, the development of immune checkpoint inhibitors has drastically changed the treatment strategy for various cancers, including genitourinary cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/iju.13902DOI Listing
February 2019
1 Read

Big Data Readiness in Radiation Oncology: An Efficient Approach for Relabeling Radiation Therapy Structures With Their TG-263 Standard Name in Real-World Data Sets.

Adv Radiat Oncol 2019 Jan-Mar;4(1):191-200. Epub 2018 Oct 12.

Australian Institute of Health Innovation, Macquarie University, Sydney, Australia.

Purpose: To prepare for big data analyses on radiation therapy data, we developed a tool-supported approach for standardization of structure names in existing radiation therapy plans. We applied the widely endorsed nomenclature standard TG-263 as the mapping target and quantified the structure name inconsistency in 2 real-world data sets.

Methods And Materials: The clinically relevant structures in the radiation therapy plans were identified by reference to randomized controlled trials. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.adro.2018.09.013DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6349627PMC
October 2018
1 Read

Role of the androgen signaling axis in genitourinary malignancies.

Transl Cancer Res 2018 Aug;7(4):1135-1142

Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.

As we learn more about the molecular biology of genitourinary malignancies, novel therapeutic strategies can be developed. This is especially crucial for prostate, renal, and bladder cancer, where mortality rates remain high especially in advanced disease states. The androgen signaling axis and the androgen receptor (AR) are areas that are actively being explored for their role in these diseases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/tcr.2018.03.41DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6349041PMC
August 2018
1 Read

Clinicopathological and Preclinical Findings of NUT Carcinoma: A Multicenter Study.

Oncologist 2019 Jan 29. Epub 2019 Jan 29.

Department of Pathology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea

Background: NUT carcinoma is a rare aggressive disease caused by fusion, and upregulation plays a key role in the pathogenesis. Here, we report on the clinicopathological characteristics of Korean patients with NUT carcinoma and the in vitro efficacy of MYC-targeting agents against patient-derived NUT carcinoma cell lines.

Materials And Methods: Thirteen patients with NUT carcinoma were evaluated for p53, C-MYC, epidermal growth factor receptor (EGFR), HER2, and programmed cell death ligand 1 (PD-L1) by immunohistochemistry. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2018-0477DOI Listing
January 2019
4 Reads

Evolution, controversies and the future of prostate cancer grading.

Pathol Int 2019 Feb 29;69(2):55-66. Epub 2019 Jan 29.

Aquesta Uropathology and University of Queensland, Brisbane, Queensland, Australia.

Histological grading of prostate cancer is one of the most important tissue-based parameters for prediction of outcome and treatment response. Gleason grading remains the foundation of prostate cancer grading, but has undergone a series of changes in the past 30 years, often initiated by consensus conference decisions. This review summarizes the most important modifications that were introduced by the 2005 and 2014 International Society of Urological Pathology (ISUP) revisions of Gleason grading and discusses the impact that these have had on current grading practices. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/pin.12761
Publisher Site
http://dx.doi.org/10.1111/pin.12761DOI Listing
February 2019
4 Reads

Association Between Cancer Incidence and Mortality in Web-Based Data in China: Infodemiology Study.

J Med Internet Res 2019 Jan 29;21(1):e10677. Epub 2019 Jan 29.

School of Public Health, Tianjin Medical University, Tianjin, China.

Background: Cancer poses a serious threat to the health of Chinese people, resulting in a major challenge for public health work. Today, people can obtain relevant information from not only medical workers in hospitals, but also the internet in any place in real-time. Search behaviors can reflect a population's awareness of cancer from a completely new perspective, which could be driven by the underlying cancer epidemiology. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2196/10677DOI Listing
January 2019
2 Reads
3.428 Impact Factor

ASF1a inhibition induces p53-dependent growth arrest and senescence of cancer cells.

Cell Death Dis 2019 Jan 28;10(2):76. Epub 2019 Jan 28.

Division of Hematology, Department of Medicine, and Center for Molecular Medicine, Karolinska Institutet and Karolinska University Hospital Solna, Stockholm, Sweden.

Anti-silencing function 1a (ASF1a) is a histone H3-H4 chaperone isoform involved in chromatin assembling and transcription regulation. Recently, ASF1a has been shown to be up-regulated in certain human malignancies and required for the expression of telomerase reverse transcriptase (TERT), a factor essential for the immortal phenotype of cancer cells; however, its role in oncogenesis remains poorly defined. In the present study, we determine whether ASF1a is required for the unlimited proliferation of cancer cells, a key cancer hallmark. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41419-019-1357-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6349940PMC
January 2019
1 Read

[A Case of Rectal Neuroendocrine Carcinoma That Showed a Sharp Turning Point after Neoadjuvant Radiochemotherapy and Conversion Surgery].

Gan To Kagaku Ryoho 2018 Dec;45(13):2006-2008

Dept. of Surgery, Kanmon Medical Center.

A 45-year-old man presented with the chief complaint of anal discomfort to a previous doctor. The symptoms remained after undergoing seton surgery following the diagnosis of intermuscular anal fistula. CT showed a tumor that was 3 cm in diameter on the right wall of the rectum, and he received a diagnosis of neuroendocrine carcinoma(NEC)based on a biopsy. Read More

View Article

Download full-text PDF

Source
December 2018
1 Read